Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 28.25p 28.25p 29.00p - - - 158,551 13:26:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -32.7 -28.3 - 74.33

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Share Charts

1 Year Motif Bio Chart

1 Year Motif Bio Chart

1 Month Motif Bio Chart

1 Month Motif Bio Chart

Intraday Motif Bio Chart

Intraday Motif Bio Chart

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:44:3528.508724.79O
11:39:4728.451,715487.92O
11:31:2428.503,000854.86O
10:45:2528.3710,5722,999.75O
10:43:0528.2530,0008,475.00O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
27/7/2017
09:20
Motif Bio Daily Update: Motif Bio is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 28.25p.
Motif Bio has a 4 week average price of 27.25p and a 12 week average price of 26p.
The 1 year high share price is 67p while the 1 year low share price is currently 21.50p.
There are currently 263,128,775 shares in issue and the average daily traded volume is 788,507 shares. The market capitalisation of Motif Bio is £74,333,878.94.
02/6/2017
09:13
ianb5004: No warrants. II,s have to bid a price in book build. I expect 34p area and very little afdded to free float. This funding uncertainty has held this back for months. No removed watch this fly Phase 3 positive Fully funded through FDA approval and marketing costs covered $1Bil market by next year. The share price could well be £1 plus by Q3 if not before.
12/5/2017
14:50
big_cat: From FT: Share price forecast The 3 analysts offering 12 month price targets for Motif Bio PLC have a median target of 90.00, with a high estimate of 125.00 and a low estimate of 25.00. The median estimate represents a 181.25% increase from the last price of 32.00. Past 12 monthsNext 12 months50.0100.0150.0● High forecast: 125 High 290.6% 125.00 Med 181.3% 90.00 Low -21.9% 25.00
24/4/2017
11:10
mikeroot5: Trader Tim's thoughts: Motif Bio, I think will head toward 50p before encountering some resistance. Longer term, the trend looks favourable for the drug company. One thing to watch for is the raising of funds to finalise Phase III testing. The placing for stage one of Phase III, amid the delayed, fumbled NASDAQ listing, hurt the share price. However, management will be raising cash from a much stronger position this time around, so I don’t expect this placing to derail share price momentum significantly. hxxp://buff.ly/2oDfmLl
18/4/2017
08:49
timbo003: There are quite a few Warrants around exercisable at 32p which could have a bit of a drag effect, I wonder if there is a clause attached to them, which can force holders to exercise them if the share price reaches and maintains a certain level, if there was that could potentially sort out any future funding issue.
14/12/2016
08:54
runwaypaul: clifflse Paratek announced today that due to faster than expected patient enrolment they expect to publish top line data for their phase 3 trials in the second quarter of 2017 rather than the original timeline of the third quarter and if successful they expect to make a new drug application in the first half of 2018 as a result their share price moved up to over $14 today hopefully Motif can soon get the message out in the states that they're also well ahead with their trials and if successful Iclaprim could be huge and lets see a bit more positive movement in our share price
07/12/2016
09:36
loveandmoney1: tradertom Motif Bio Market Cap: £40.45m Price: 22.375p Spread: 2% Motif Bio is a company that I like a lot especially at its current price. The company has a potentially ground-breaking antibiotic. There has not been a new class of antibiotics discovered since the 1980s. The UK government recently commissioned Lord Jim O’Neill to report on this issue. His findings warned that medicine could be “cast back into the dark ages”. Similarly, other governments are reviewing their drugs policy. As bacterial infections evolved over time they have developed a resistance to common bacterial infections. This is significant because many classes of antibiotics are now becoming obsolete. In May, an infection resisted Colistin, an antibiotic discovered in China at the end of 2015, which was significant because it was commonly relied on when other forms of antibiotic failed. An infection is yet to be discovered, which can resist all classes of antibiotics. However, on our current trajectory, this is isn’t far away. Iclaprim – Motif Bio’s new antibiotic – has proved in early-stage trials it has the potential to succeed where existing antibiotics are failing. Therefore, should the drug jump through the necessary regulatory hoops, there will be significant demand awaiting it. The share price has really fallen out of love with investors. The company have struggled with financing. They intended to list on the NASDAQ to open up some greater funding potential for life-science ventures such as theirs. However, this was hit by delays. NASDAQ regulators also required the company to place additional shares on their European index, which was an additional unpleasant surprise for investors and meant further dilution. It was all a bit messy with delays and unexpected hurdles, which frightened a lot of investors off. Now, it appears the funding problems seem to be out the way for now. The company has raised the funds it needs to complete the third phase of clinical trials. That said, it will need additional funds after this. However, much of the complication this time around was related to the NASDAQ listing, rather than simply raising funds. As a result, much of the pain is now out of the way. The shares have fallen over 50% in 6 weeks and are currently trading at a third of the price they were 6 months ago. Paratek Pharmaceuticals, Motif’s nearest competitor is currently valued at just under $300 million compared to Motif Bio’s paltry £40 million market cap. Despite the complications, Motif’s business proposition remains unchanged. There is still overwhelming demand for a development in this space. The fundamentals are unchanged. I really think that this stock is oversold due to recent unsavoury funding issues, which now mostly have been resolved. Real value here, I think.
19/11/2016
21:48
colebrooke: Twitter hashtag $MTFBWhatever you think of Twitter it reaches a wide audience.I've noticed increased coverage in the last day or so particularly from the US on the hashtag $MTFB.My point is the stock is gaining coverage amongst the Twitter stock/share trading audience. This should impact positively on interest in the stock and therefore drive Nasdaq trading and the share price.
12/8/2016
15:58
123prezzie: lanb5004. In your post 706 you say that the 'main holder' is supporting the NASDAQ fund raising. You don't say who you consider to be the main holder. If it is Amphion (AMP), who held 26% at 31/12/15, then I suggest you need to define what you mean by 'support'. AMP appears to be pretty short of cash and has already pledged well over half its MTFB shares as collateral against loans charging 10% (!) interest. The latest tranche is covered by the MTFB RNS above dated 18/7/16 where AMP has borrowed $750,000 with 1.4m MTFB shares as security ie an implied value of about 42p/share. Followers of Quindell and similar will know that the way these deals usually work is that the lender, probably with the benefit of a Put arrangement, sells if the share price falls near 42p, thus recouping the loan. MTFB is unlikely to survive for many months unless it can convince investors that its products will be successful. I strongly recommend that any investor, actual or potential, should read the AMP and MTFB accounts and then tell me if/where I am wrong.
15/7/2016
07:36
apad: IC: MOTIF BIO (MTFB) What we said: Buy When: 28 April 2016 Price: 42p Share price change to date: +14% Antibiotics specialist Motif Bio (MTFB) is looking stateside for its next injection of capital to help fund the final trial of its ground-breaking antibiotic iclaprim. The Aim-traded company has filed an application to list on the tech-heavy US Nasdaq index and plans to raise up to $60m (£45m) in the process. It’s not just for the money that this listing is attractive. Joining Nasdaq brings Motif closer to the Food and Drug Administration (FDA) – the regulatory body in the US which is responsible for approving all new drugs before launch into the world’s biggest healthcare market. Furthermore, US investors are generally thought to be less risk averse and therefore may be more willing to provide funds for the clinical trial as well as bidding up the share price. With the potential to launch the first new class of antibiotic for 30 years, Motif Bio is certainly an exciting company. Now, with easier access to cash thanks to a US listing, the investment case looks all the more attractive. Buy at 48p. MB Buy
18/8/2015
10:53
regandharry5: Antibiotics in the news again, every time the over use of current antibiotics and how ineffiecent they are is raised the MTFB share price rises.
Motif Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170727 14:42:41